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BOUSQUET ET AL 71The selection of pharmacotherapy for patients with allergic
rhinitis aims to control the disease and depends on many
factors. Grading of Recommendations Assessment,
Development and Evaluation (GRADE) guidelines have
considerably improved the treatment of allergic rhinitis.
However, there is an increasing trend toward use of real-world
evidence to inform clinical practice, especially because
randomized controlled trials are often limited with regard to the
applicability of results. The Contre les Maladies Chroniques
pour un Vieillissement Actif (MACVIA) algorithm has proposed
an allergic rhinitis treatment by a consensus group. This simple
algorithm can be used to step up or step down allergic rhinitis
treatment. Next-generation guidelines for the pharmacologic
treatment of allergic rhinitis were developed by using existing
GRADE-based guidelines for the disease, real-world evidence
provided by mobile technology, and additive studies (allergen
chamber studies) to refine the MACVIA algorithm. (J Allergy
Clin Immunol 2020;145:70-80.)
Key words: Allergic rhinitis, Allergic Rhinitis and Its Impact on
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FIG 2. Development of next-generation ARIA guidelines.
FIG 1. Organizations supporting the meeting (Paris; December 3, 2018). CEmPac, Centre for Empowering
Patients and Communities; EAACI, European Academy of Allergy and Clinical Immunology; EIT Health,
European Institute for Innovation and Technology; EFA, European Federation of Allergy and Airways
Diseases Patients’ Associations; ERS, European Respiratory Society; Euforea, European Forum for Research
and Education in Allergy and Airways Diseases; GA2LEN, Global Allergy and Asthma European Network;
GARD, Global Alliance against Chronic Respiratory Diseases (WHO Alliance); GINA, Global Initiative for
Asthma; POLLAR, Impact of Air Pollution in Asthma and Rhinitis; SFA, Societe française d’Allergologie;
SPLF, Societe de Pneumologie de Langue Française; WAO, World Allergy Organization.
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BOUSQUET ET AL 73to use real-world data to inform clinical practice, especially
because randomized controlled trials are often limited to
the applicability of results.13 The tradeoff that is made
is one between risk of bias, primarily selection and
confounding bias, and applicability. Ideally, both types of
evidence are merged.
Guidelines are not sufficiently followed because they are not
close enough to patients’ needs and probably do not reflect real
life. In cluster-randomized trials guideline-driven treatment is
more effective than free treatment choice.14,15 Moreover,
guidelines (in rhinitis but also in asthma) have led to a
better understanding of the treatment of the disease and have
had an important teaching role that has led to change
management.16
In addition, there is a need to support transformation of the
health care system for integrated care with organizational health
literacy.16,17 During a recent meeting held in Paris (December 3,
2018) for chronic disease care, Mobile Airways Sentinel Network
(MASK)18 and Impact of Air Pollution on Asthma and
Rhinitis (POLLAR; European Institute for Innovation and
Technology–Health [EIT Health]),19 in collaboration with
professional and patient organizations in the field of allergy and
airway diseases (Fig 1), recommended the evaluation of
real-life care pathways (integrated care pathways [ICPs])
centered around the patient with rhinitis and asthma.
During the ICPmeeting in Paris, next-generation guidelines for
the pharmacologic treatment of allergic rhinitis were developed
by using existing GRADE-based guidelines for allergic
rhinitis,5,20-22 RWE provided by randomized controlled trials,
real-world data using mobile technology,23,24 and chamber
studies (Fig 2).5,6,16-20,25-27 These recommendations were used
to refine the algorithm for allergic rhinitis treatment proposed
by a consensus group.5The present report describes the process of next-generation
Allergic Rhinitis and Its Impact on Asthma (ARIA)–GRADE
guidelines for the pharmacologic treatment of allergic rhinitis.DOCUMENTS CONSIDERED FOR DEVELOPMENT
OF ARIA CARE PATHWAYS
Contre les Maladies Chroniques pour un
Vieillissement Actif (MACVIA) algorithm proposing
a stepwise approach for allergic rhinitis
pharmacologic treatment
An algorithm based on the visual analogue scale (VAS)28 has
been devised by the ARIA expert group (1) for selection of
pharmacotherapy for patients with allergic rhinitis and (2) to
A
B
FIG 3. A, Step-up algorithm in untreated patients using VASs (adolescents and adults).5 The proposed
algorithm considers the treatment steps and the patient’s preference. VAS levels are shown in ratios. If
ocular symptoms remain once treatment has been initiated, add intraocular treatment. B, Step-up algorithm
in treated patients using VASs (adolescents and adults).5 The proposed algorithm considers the treatment
steps and the patient’s preference. VAS levels are shown in ratios. If remaining ocular symptoms, add
intraocular treatment.
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ARIA algorithm for allergic rhinitis was revised by an expert
group, and a proposal was made to classify allergic rhinitis
treatments (Table I).6ARIA 2010, 2016 revision, and US Practice
Parameters 2017
Although few head-to-head comparisons ofmedications during
randomized controlled trials are available,29-32 the comparison of
TABLE II. Overall recommendations using GRADE
ARIA 201621
1. In patients with SAR, we suggest either a combination of
INCS 1 OAH or INCS alone, but the potential net benefit might not
justify spending additional resources.
2. In patients with PAR, INCSs alone are recommended rather than a
combination of an INCS 1 an OAH.
3. In patients with SAR, we suggest either a combination of an
INCS 1 an INAH or an INCS alone, but the choice of treatment de-
pends on patient preferences. At initiation of treatment (first 2 weeks),
a combination of an INCS 1 an INAH might act faster than an INCS
alone and might therefore be preferred by some patients. In settings in
which the additional cost of combination therapy is not large, a com-
bination therapy might be a reasonable choice.
4. In patients with PAR, we suggest either a combination of an
INCS 1 an INAH or an INCS alone.
For all of these recommendations, the level of evidence was low2,3 or very
low.1,4
US practice parameters 201722
For initial treatment of nasal symptoms of SAR in patients >_12 years of age,
clinicians:
d should routinely prescribe monotherapy with an INCS rather than
a combination of an INCS and an oral H1-antihistamine or
d should recommend an INCS over an LTRA (for >_15 years of age).
d For moderate-to-severe symptoms, clinicians can recommend the
combination of an INCS and an INAH.
INAH, Intranasal antihistamine; LTRA, leukotriene receptor antagonist; OAH, oral
antihistamine; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.
TABLE I. Classification of treatments used in patients with
allergic rhinitis6
T1 Nonsedating H1-antihistamine (oral, intranasal, and ocular),
leukotriene receptor antagonists, or cromones (intranasal and
ocular)
T2 INCSs
T3 INCSs 1 intranasal azelastine
T4 Oral corticosteroid as a short course and an add-on treatment
T5 Consider referral to a specialist and allergen immunotherapy
J ALLERGY CLIN IMMUNOL
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reviews1 and guidelines.5,20-22 A health technology assessment
evaluation concluded that most allergic rhinitis medications had
a similar effect.33 However, this study used a method that did
not enable differentiation between medications.
The ARIA revision 201621 and US Practice Parameters 201722
were developed independently and used the samemethodological
approach: GRADE.10-12 Interestingly, the same questions were
considered. Two major outcomes were considered in the
treatment of moderate-to-severe rhinitis: efficacy and speed of
action (Table II).21,22
Although the GRADE approach suggests the use of all relevant
evidence, developers of recommendations have focused on
randomized controlled trials.
ARIA 2016 revision21 and US Practice Parameters 201722
mainly based on Randomized Control Trials support the MACVIA
algorithm.5Speed of onset of action of medications
The US Food and Drug Administration has proposed 3 study
types to assess the onset of action of allergic rhinitis
medications25,34: the standard phase III double-blind randomized
controlled trial, park setting studies, and allergen exposure
chamber studies.35 Randomized controlled trials are informative
but cannot provide sufficient precision to assess onset of efficacy
because they cannot allow repeated timing over short periods of
time (minutes). Allergen exposure chambers offer some
advantages over randomized controlled trials in assessing the
onset of action of medications that can be demonstrated in
minutes.35 The allergen exposure chamber allows consistent
allergen exposure. However, it is a manipulated in vivo procedure,
whereas the park study mirrors real-life exposure. Park studies
have not captured both the early time and the allergen exposure
chamber. It appears that a crossover trial would be difficult with
a park study because of variations in allergen exposure between
days. On the other hand, the allergen exposure chamber cannot
replace real-world allergen exposure but can only complement
it. Allergen exposure chamber studies appear more robust than
park studies. To date, the allergen exposure chamber studies
that have been conducted have been monocentric and have
followed protocols unique to each center. Because there are
technical differences in each allergen exposure chamber, it is
not easy to compare the results obtained in the different allergen
exposure chambers,36 although standardization has begun for
some of them.37
In the Ontario and Vienna allergen exposure chambers, several
medications have been tested (Table III).26,27,38-51The Ontario chamber studies show the rapid onset of efficacy
for azelastine and its combinations. There does not seem to be a
difference between azelastine alone or in combination. Other
intranasal H1-antihistamines have a slower onset of action.
Intranasal corticosteroids (INCSs; alone or with oral
H1-antihistamines) are not effective before 2 hours. The Vienna
chamber studies show that azelastine and levocabastine/
fluticasone furoate are the fastest-acting medications by
comparison with oral H1-antihistamines.
RWE using mobile technology
According to the World Health Organization (WHO), Mobile
Health (mHealth) has the potential to transform health service
delivery globally.52 Next-generation ARIA guidelines should
consider testing recommendations based on the GRADE
approach with direct RWE by using data obtained by using
mHealth tools to confirm or refine current GRADE-based
recommendations.
Although many mHealth tools are available for the assessment
of allergic rhinitis,53 only MASK has reported data on
medications that can be used in RWE.MASK, a new development
of ARIA, is an information and communication technology
system centered around the patient (adolescents and adults).19,54
MASK, which is freely available in the Google Play and Apple
Stores, can inform patient decisions on the basis of a self-care
plan proposed by the health care professional.18,19 It uses a
treatment scroll list including all medications customized for
each country, as well as VASs to assess rhinitis control and
work productivity. MASK is deployed in 23 countries and 17
languages,55 with more than 30,000 users. It was selected by
the European Commission’s Directorate-General for Health and
Food Safety and by the newly established Commission Expert
Group ‘‘Steering Group on Health Promotion, Disease Prevention
TABLE III. Comparison of the time of onset of action using environmental exposure chambers
Drug (dose) Formulation Onset of action Parameter Reference
Ontario environmental exposure chamber38
Azelastine Nasal spray 15 min TNSS 38
MPAzeFlu
Fluticasone propionate 1 oral loratadine (10 mg)
Nasal spray




Olopatadine Nasal spray 90 min TNSS 39
Ciclesonide Nasal spray 60 min TNSS 40
Budesonide Nasal spray 8 h TNSS 41
Budesonide and azelastine Nasal spray 20 min
CDX-313 (solubilized budesonide 1 azelastine) Nasal spray 20 min
Levocetirizine Tablet 160 min MSS 42
Vienna environmental exposure chamber
Astemisole-D, Loratadine-D Tablet 65-70 min No placebo
MSS
43
Astemisole, loratadine, terfenadine-forte Tablet 107-153 min No placebo
MSS
44
Azelastine (intranasal), desloratadine Nasal/tablet Azelastine: 15 min Desloratadine: 150 min TNSS 45
Bilastine, cetirizine, fexofenadine Tablet No assessment before 60 min TNSS 46
Cetirizine-D, budesonide Nasal/tablet No placebo 47
Cetirizine-D, xylometazoline nasal spray Nasal/tablet No placebo 48
Desloratadine Tablet 30 min Obstruction 49
Fluticasone furoate and levocabastine Nasal spray Combi: 15 min No data for fluticasone
furoate or levocabastine
TNSS 50
Levocetirizine, loratadine Tablet Levocetirizine: 45 min Loratadine: 60 min MSS 51
Rupatadine Tablet 15 min TNSS 52
Aze, Azelastine hydrochloride; MSS, mixed symptom score; TNSS, total nasal symptom score.
TABLE IV. Information used to support next-generation ARIA-GRADE guidelines
GRADE recommendation mHealth RWE Chamber studies
Oral H1-antihistamines are less potent than INCSs BUT many







Intranasal H1-antihistamines are less effective than INCSs 21
Intranasal H1-antihistamines are effective within minutes 21 40, 46
INCSs should continue being prescribed as first-line therapy in
patients with moderate-to-severe rhinitis
21, 23 24, 25
Onset of action of INCSs takes a few hours to a few days
(ciclesonide has a faster onset)
21 42, 43
The combination of INCSs and oral H1-antihistamines offers no
advantage over INCSs
22, 23 24, 25
The combination of INCSs and intranasal H1-antihistamines is
more effective than INCSs





The combination of INCSs and intranasal H1-antihistamines is
effective within minutes
39, 43, 51
Leukotriene antagonists are less potent than INCSs 23 39, 43, 51
The studies are summarized in the Online Repository.
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practice that can be scaled up in the field of digitally enabled,
integrated, person-centered care.56
Messages from MASK. Two studies in more than 9000
users and 22 countries24,57 confirmed a pilot study23 and allowed
differentiation between allergic rhinitis treatments. They also
showed that the assessment of days was useful in understanding
treatment patterns. Their results combine to indicate that the
following are true in real life:1. Patients are poorly adherent to treatment.23,57
2. No treatment trajectory could be identified,24 and most
patients self-medicate.
3. Most patients with rhinitis use on-demand treatment
when their symptoms are suboptimally controlled.
When symptoms are uncontrolled, they change their
medications daily for control.23
4. The vast majority of patients do not follow guidelines or
physicians’ prescriptions.23,24,57
TABLE V. Consensus opinion for the different scenarios6
Part 1: Approach to treatment
Patient VAS Phenotype Tx Consensus
1 >_5 IAR or PER Yes Step-up
2 >_2 to <5 IAR Yes Continue
3 <2 IAR Yes Step-down
4 >_2 to <5 PER Yes Continue or step-up
5 <2 PER Yes Step-down
6 >_5 IAR No Initiate
7 >_5 PER No Initiate
8 <5 IAR or PER No Initiate
Part 2: Specific treatment step-ups
Current Tx Step-ups Notes
9 T1 T2 or T3
10 T2 T3
11 T3 T3 1 T4* Consider T5
12 T1 1 T2 T3 Consider T5
13 T1 1 T3 T3 1 T4* Consider T5
14 T2 1 T3 T3 1 T4 Consider T5
15 T5 1 VAS >_5 T5 1 T>2 or T3
16 T5 1 VAS >_2 to <5 T5 1 T1, T2 or T3 T5 1 T2 or T3 if congestion
17 T5 1 T1 T5 1 T2 or T3
18 T5 1 T2 T5 1 T3
19 T5 1 T3 Continue Consider referral
Part 3: Specific treatment step-downs
Current Tx Step-down Notes
20 T3 T2 or T1 T2 if congestion
21 T2 T1 Continue T2 if congestion
22 T1 Stop Not exposed to allergen
23 T1 Continue Exposed to allergen
24 T1 1 T2 T1 or T2 T2 if congestion
25 T1 1 T3 T1 or T3 T3 if congestion
26 T2 1 T3 T2 or T3
27 T5 1 T3 T5 1 T1 or T2 T5 1 T2 if congestion
28 T5 1 T2 T5 1 T1 Continue T5 1 T2 if congestion
29 T5 1 T1 T5 Not exposed to allergen
30 T5 1 T1 T5 1 T1 Exposed to allergen
31 T5 T5 Until end of course
Part 4: Treatment initiation
Patients Tx Consensus Note
32 IAR; VAS >_5 No T1, T2, or T3 T2 or T3 if congestion
33 PER; VAS >_5 No T2 or T3
34 IAR or PER VAS <5 No T1, T2, or T3 T2 or T3 if congestion
IAR, Intermittent allergic rhinitis; PAR, persistent allergic rhinitis; T1, antihistamine (oral, intranasal, or eyedrop), leukotriene receptor antagonist or cromones (intranasal or
eyedrops); T2, INCS; T4, INCS 1 intranasal antihistamine; T5, consider referral and allergen immunotherapy; Tx, treatment.
*Short course (3-7 days).
If VAS score remains >_5/10.
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suggesting the need for behavioral science to improve
control.
6. Patients who do not take medications usually have
well-controlled symptoms.23,24
7. Patients reporting monotherapy with INCS-containing
medications have a similar control level.23,24 However,
azelastine–fluticasone propionate combination (MPAze-
Flu) is significantly more often administered as a single
therapy than fluticasone furoate or mometasone furoate.8. Patients reporting oral H1-antihistamine monotherapy
have a poorer level of control than those reporting
INCS-containing medications.23,24
9. Most patients have a worse control level with increasing
medications,23,24 contradicting guidelines that propose to
increase the treatment level to achieve control.
10. These results indicate that when patients’ symptoms are
controlled, either they do not take a medication or remain
with a single treatment. When their symptoms are
uncontrolled, they comedicate.
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more effective than INCSs.23,24
12. Resistant hypertension is defined by the number of
medications used to control the disease,59 and a similar
classification might be proposed in patients with allergic
rhinitis, confirming the severe chronic upper airway
disease concept.60
Limitations of MASK. As for all studies using participatory
data, potential biases include (1) the likelihood of sampling bias,
which makes it difficult to assess the generalizability of the study;
(2) outcome misclassification that cannot be assessed; and
(3) because of ethical considerations, availability of very little
information on patient (or day) characteristics. App users are not
representative of all patients with rhinitis.
MASK studies have used days in cross-sectional analyses18,19
because there is no clear pattern for a defined treatment, and a
longitudinal study was not feasible because users mostly use
the app intermittently.
The diagnosis of allergic rhinitis was not supported by a
physician but was a response to the following question: ‘‘Do you
have allergic rhinitis? Yes/no.’’ Therefore some users with no
rhinitis might have responded ‘‘yes’’ to the question, but more
than 95% of responders declared symptoms of rhinitis by
questionnaire. There are potential measurement biases when
using apps, including collection of information, education of the
patient, age, availability, and ability to use a smartphone.23
Precise patient characterization is impossible using an app, but
every observational study using MASK has been able to identify
days with poor control or criteria of severity.61-65
Adherence to treatment is impossible to obtain directly because
patients do not report data every day and might not report all
medications used. Electronic counters on delivery devices could
be used to obtain more complete data on adherence.
Nonetheless, mobile technology is becoming an important tool
for better understanding and managing allergic rhinitis. It adds
novel information that was not available with other methods.61-67
In addition, the mere number of observations that mobile
technology can provide offers an unprecedented body of evidence
that can complement conventional randomized controlled trials
for RWE.
Other RWE studies using mobile technology. To our
knowledge, no other mHealth study has assessed the efficacy of
different medications on a large scale.Physician’s perspectives
There is a complete disconnection between the physician’s
prescriptions and the patient’s behavior for the treatment of
pollen-induced allergic rhinitis. The vast majority of allergists
prescribe medications for the entire season, recommending the
patient to use them regularly, even during days with few
symptoms. Some allergists prescribe a preseason treatment
without clear evidence of efficacy. On the other hand, the vast
majority of patients use their medications on demand when their
allergic rhinitis is not well controlled and they do not follow
guidelines.18,19
When physicians are patients themselves, they behave like
patients when they treat their own allergic rhinitis and do not
follow the prescriptions, as recently reported.58 Health literacy is
an important component of adherence to medications,68,69 butgiven the behavior of allergists as patients, it appears that other
factors aremore important. Possibly, it is human nature that drives
adherence to treatment irrespective of whether the patient is a
physician, and behavioral science is an important need to be
considered in medical care.
Lack of adherence is very common in allergists with allergic
rhinitis and prescribed long-term treatment.NEXT-GENERATION ARIA-GRADE GUIDELINES
Recommendations have been refined with RWE and chamber
studies (Table IV).20-24,38,39,41,42,45,50 The algorithm proposed in
Fig 3 is also supported by the present data.
The approach proposed in this article confirms most GRADE
recommendations for allergic rhinitis and the classification of
allergic rhinitis treatments proposed by ARIA (Table I).6 Some
conditional evidence was supported by RWE:
d The combination of oral H1-antihistamines with INCSs was
not found to be more effective than INCSs alone.
d The combination of intranasal H1-antihistamines with
INCSs was found to be more effective than INCSs alone.
d Intranasal H1-antihistamine–containing medications are
effective within minutes.
NEXT-GENERATION ARIA ALGORITHM
The overall ARIA algorithm5 was found to be appropriate, and
no change is needed. The step-up and step-down approach
proposed by ARIA experts6 based on the ARIA algorithm has
been confirmed (Table V). However, the different steps need
further validation with RWE.CONCLUSIONS
In this report we present the first GRADE-based guideline
integrating RWE and supportive studies (chamber studies) in the
management of allergic rhinitis. This approach could be
considered a model for chronic diseases.
These guidelines will inform ICPs and will be included in the
European Commission’s Directorate-General for Health and
Food Safety digitally-enabled, integrated, person-centered
care.70 They will represent the change management strategy of
ARIA, phase 4.16
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SUPPLEMENTARY DATA
Although many mHealth tools are available for the assessment
of AR,E1 onlyMASK has reported data onmedications that can be
used in RWE. MASK, a new development of ARIA, is an
information and communication technology system centered
around the patient in adolescents and adults.E2,E3 MASK, which
is freely available in the Google Play and Apple stores, can
inform patient decisions on the basis of a self-care plan
proposed by the health care professional.E2,E4-E11 It uses a
treatment scroll list including all medications customized for
each country and a VAS to assess rhinitis control and work
productivity. MASK is deployed in 23 countries and 17
languages,E12 with more than 26,000 users. It was selected by
the European Commission’s Directorate-General for Health and
Food Safety and the newly established Commission Expert Group
‘‘Steering Group on Health Promotion, Disease Prevention and
Management of Non-Communicable Diseases’’ as a good
practice in the field of digitally enabled, integrated,
person-centered care.E13
2016 MASK treatment studyE7
Background. A pilot study attempted to provide additional
and complementary insights into real-life treatment of allergic
rhinitis using MASK.
Methods. MASK collected daily VAS scores for overall
allergic symptoms (VAS global) in 15 countries. Because of
privacy concerns, MASK, as any other mobile technology, cannot
assess the characteristics of the patient.
Results. Two thousand eight hundred seventy-one users filled
in 17,091 days of VASs between June 1, 2015, and May 30, 2016.
Medications were reported for 9,634 days.
d Patients did not follow guidelines and often self-medicated.
d Adherence to treatment was poor.
d MASK allowed differentiation between treatments within
or between classes (INCS containing medications and
oral H1-antihistamines). Untreated days (days reported
without any treatment) had the best control. Days with
reported INCSs or MPAzeFlu had similar control. Days
with cetirizine alone had worse control. Days with
loratadine alone or any cotherapy had the worst control.
d Users reporting intranasal MPAzeFlu used comedication on
30% to 35% of days, whereas those reporting INCSs used
comedication on 45% to 60% of days.
d Very few users reported oral corticosteroids, and VAS
levels were usually high.
d This RWE study brings new information on the treatment
of patients with AR, suggesting the following: First,
patients treat themselves as needed depending on disease
control and increase their treatment when they are unwell.
However, comedication does not improve the median
control. Second, MPAzeFlu is superior to INCSs because,
when symptoms are controlled, patients do not comedicate,
and comedication is more common in those who used
INCSs.
The MASK 2016 study indicated low adherence and allowed
comparative efficacy of medications by using a novel approach.
2017 MASK treatment studyE14
Objectives. A cross-sectional real-world observational study
was undertaken in 22 countries to complement the 2017 pilot
study.E7
Methods.MASKwas used to collect data of daily VAS scores
for (1) overall allergic symptoms; (2) nasal, ocular, and asthma
symptoms; and (3) work, as well as medication use. The 3 most
common intranasal medications containing INCSs (fluticasone
furoate, mometasone furoate, and fluticasone propionate),
MPAzeFlu, and 8 oral H1-antihistamines were studied. The study
included some of the users of the pilot study (to achieve a
sufficient number of users per drug), E7 but outcomes differed.
Results. Nine thousand one hundred twenty-two users filled
in 112,054 days of VASs in 2016 and 2017 (Fig E1).
d As shown in the pilot study,E7 similar control levels were
found for single treatment with INCSs or MPAzeFlu
(good control), but more users needed INCSs to be
combined with another treatment (worst control) compared
with MPAzeFlu.
d INCSs or MPAzeFlu resulted in more control days than oral
H1-antihistamines.
d The same trend was found for VAS scores for asthma, eye
symptoms, and work productivity.
The 2017 MASK treatment study confirms MASK’s usefulness
in assessing behavior in patients with allergic rhinitis.
A ranking of medications was possible and confirmed the
MASK 2016 study. The 2 MASK treatment studies indicated that
MPAzeFlu is the most effective and oral H1-antihistamines are
the least effective category of medication.
2018 MASK adherence studyE15
Background. Mobile technology might help better
understand adherence to treatment.
Objectives. We sought to assess adherence to treatment in
patients with allergic rhinitis using the MASK app.
Methods. An observational cross-sectional study was carried
out on all consecutive users who filled in MASK from January 1,
2016, to August 1, 2017. Secondary adherence was assessed by
using modified medication possession ratio (MPR) and
proportion of days covered (PDC is a newer and more
conservative measure of refill record–based adherence).
d Proportion of MPR (modified MPR): ratio of days of
medication use was reported to be used on days in a given
time interval.
d PDC over a time interval (modified PDC): ratio of days of
medication was reported to be used on days in the time
interval between the first and the last record considered.
Results. Twelve thousand one hundred forty-three users were
registered, and 6949 users had at least 1 VAS recording. Among
them, 1887 (15.7%) users had 7 or more days of reporting VAS
scores. One hundred thirty-six (11.28%) of them were adherent
(MPR >_ 70% and PDC <_ 1.25).
The 2018 MASK adherence study indicated that adherence to
treatment was estimated to be less than 5%.
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FIG E1. Efficacy of INCS-containing medications (VAS global) and percentage of days with comedications.
FF, Fluticasone furoate;MF, mometasone furoate;OAH, oral H1-antihistamine;Other, any other medication;
Single, no comedication.
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